• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » SEC dings Deerfield Capital Management $2M for short-selling violations

SEC dings Deerfield Capital Management $2M for short-selling violations

September 17, 2013 By Brad Perriello

SEC dings Deerfield Management $2M for short-selling violations

Deerfield Capital Management agreed to pay $1.9 million to the SEC to settle violations of the financial watchdog’s short-selling rules in stocks including Insulet (NSDQ:PODD), Derma Sciences (NSDQ:DSCI) and TearLab Corp. (NSDQ:TEAR).

It’s part of an SEC crackdown on illegal short sales of stock that the agency announced today. The SEC said it slapped 23 investment firms with short-selling violations, reeling in more than $14.4 million in "monetary sanctions," according to an agency press release.

In short selling, an investor sells shares and agrees to repurchase them later, assuming that the share price will have fallen by then – in effect, it’s a bet that the shares will be bought back at lower price than they were sold for, with the difference going into the investor’s pocket. The risk is that the share price rises, meaning the investor is out of pocket for the difference.

The SEC said its Rule 105 "prohibits the short sale of an equity security during a restricted period – generally 5 business days before a public offering – and the purchase of that same security through the offering," according to the release.

Deerfield shorted shares of Insulet, Derma Sciences, TearLab and other companies, netting some $1.3 million in illicit profits, according to the SEC. Deerfield agreed to repay those profits, plus another $19,000 in prejudgment interest and $610,000 in penalties.

Late last year and early this year Deerfield sold short about 268,900 PODD shares for an average price of $21.56 apiece during the restricted period ahead of a follow-on offering priced at $20.75 per share, , according to the SEC. Deerfield’s allotment in the offering was 275,000 shares, resulting in proceeds of $217,237 plus more than $5,000 from buying up the remainder at a discount, for total illicit profits of nearly $223,000, the agency said.

Deerfield pulled in about $141,000 when it shorted more than 233,000 shares of DSCI stock ahead of that company’s follow-on offering, selling for $9.28 apiece and buying for $9.25 each, then buying another 267,000 shares at a discount, according to the SEC. The investment firm pulled in $32,000 for short-selling about 65,000 TEAR shares in another follow-on, selling for $3.89 per share and buying for $3.60 each, then snapping up another 35,000 shares at a discount, the SEC said.

Filed Under: News Well, Wall Street Beat Tagged With: Deerfield Management, Derma Sciences Inc., Insulet, Securities & Exchange Commission (SEC), Tearlab Corp.

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy